{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:07:02Z","timestamp":1794967622890,"version":"4.9.1"},"reference-count":17,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed\/refractory follicular lymphoma (r\/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1\u20133A FL were required to be r\/r after \u22652 therapy lines including an anti-CD20 and an alkylator. After first becoming r\/r, patients were required to initiate \u22651 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow-up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT-D), event-free survival (EFS), and overall survival (OS). One hundred eighty-seven patients were identified. Most patients\u2019 (80.2%) index therapy occurred in third line (3L) (range, 3L\u20136L). Median follow-up from FL diagnosis was 9 years (range, 1\u201321 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0-18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r\/r to both an anti-CD20 monoclonal antibody and an alkylator) or POD24 (progressed \u226424 months after front-line anti-CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR-5), ReCORD-FL presents a valuable source of control data for comparative studies in r\/r FL.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000745","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T15:00:17Z","timestamp":1655823617000},"page":"e745","source":"Crossref","is-referenced-by-count":31,"title":["A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)"],"prefix":"10.1002","volume":"6","author":[{"given":"Gilles","family":"Salles","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, LMU Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers E. M.","family":"Patten","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centre, King\u2019s College London, United Kingdom"},{"name":"Haematology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Germany"},{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Smith","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, The University of Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jim\u00e9nez-Ubieto","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Davis","sequence":"additional","affiliation":[{"name":"Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Nagar","sequence":"additional","affiliation":[{"name":"Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Bollu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Jousseaume","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ramos","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7]]},"reference":[{"key":"R1-20231117","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs.","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"},{"key":"R2-20231117","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the gela-goelams fl2000 study.","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"R3-20231117","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-20231117","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the german low-grade lymphoma study group.","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"R5-20231117","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/annonc\/mdf119","article-title":"Survival after progression in patients with follicular lymphoma: analysis of prognostic factors.","volume":"13","author":"Montoto","year":"2002","journal-title":"Ann Oncol"},{"key":"R6-20231117","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival.","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"R7-20231117","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"R8-20231117","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-cvp versus r-chop versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the follo5 trial conducted by the fondazione italiana linfomi.","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"R9-20231117","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"R10-20231117","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study.","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"R11-20231117","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"R12-20231117","first-page":"40","article-title":"Primary analysis of zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-hodgkin lymphoma (iNHL).","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"R13-20231117","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 elara trial.","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"R14-20231117","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R15-20231117","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor t cells in refractory b-cell lymphomas.","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"R17-20231117","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.2217\/fon-2018-0317","article-title":"Using response evaluation criteria in solid tumors in real-world evidence cancer research.","volume":"14","author":"Feinberg","year":"2018","journal-title":"Future Oncol"},{"key":"R18-20231117","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the united states: data from the observational national lymphoCare study.","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:08:41Z","timestamp":1702922921000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000745","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]}}}